STOCK TITAN

Mineralys Therapeutics (MLYS) insider details stock option exercise and sales

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Mineralys Therapeutics, Inc. has a planned sale of common stock by an affiliate through Merrill Lynch on NASDAQ, related to an exercise of employee stock options using a broker-assisted cashless exercise on 07/13/2026. In the prior three months, David Rodman reported multiple open-market sales of the company’s common stock on various dates in April, May, June, and July 2026, with individual transactions ranging from a few hundred to over 14,000 shares and aggregate dollar values per trade from tens of thousands to over $400,000.

Positive

  • None.

Negative

  • None.
Shares Outstanding 82,498,101 shares Common stock outstanding as referenced in the Form 144
Sale on 04/13/2026 14,058 shares for $373,086.81 Common stock sold by David Rodman on 04/13/2026
Sale on 05/13/2026 14,056 shares for $401,789.92 Common stock sold by David Rodman on 05/13/2026
Sale on 06/15/2026 9,890 shares for $235,487.24 Common stock sold by David Rodman on 06/15/2026
Sale on 06/17/2026 4,584 shares for $114,600.00 Common stock sold by David Rodman on 06/17/2026
Form 144 regulatory
"144: Filer Information | | | 144: Filer Information"
Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.
Exercise of employee stock options financial
"Common Stock | 07/13/2026 | Exercise of employee stock options"
broker assisted cashless exercise financial
"14058 | 07/13/2026 | Broker assisted cashless exercise"
Common stock financial
"Common Stock | 04/13/2026 | 14058 | 373086.81"
Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What does Mineralys Therapeutics (MLYS) report in this Form 144?

Mineralys Therapeutics reports a planned sale of common stock on NASDAQ by an affiliate, tied to an exercise of employee stock options via a broker-assisted cashless exercise on 07/13/2026.

Who is the selling security holder in the Mineralys Therapeutics (MLYS) Form 144?

The selling security holder disclosed is David Rodman, with an address in Radnor, Pennsylvania, who has reported multiple common stock sales of Mineralys Therapeutics, Inc. during the past three months.

What recent stock sales by David Rodman are disclosed for MLYS?

Disclosed sales include trades such as 14,058 shares on 04/13/2026 for $373,086.81 and 14,056 shares on 05/13/2026 for $401,789.92, among several smaller transactions between April and July 2026.

What was the largest individual transaction value reported for MLYS stock?

Among the listed transactions, the largest individual aggregate value is $401,789.92 from a sale of 14,056 shares of Mineralys Therapeutics common stock on 05/13/2026.

How many Mineralys Therapeutics (MLYS) shares are indicated as outstanding?

The filing indicates that Mineralys Therapeutics has 82,498,101 shares of common stock outstanding, providing context for the relative size of the reported sales by the affiliate holder.

What is a broker-assisted cashless exercise in the MLYS Form 144?

A broker-assisted cashless exercise allows option holders to exercise employee stock options and simultaneously sell enough shares through a broker to cover the exercise cost, with the balance typically delivered as shares or cash.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature